Research Projects for Molecular Imaging Inflammation in Cancer (PAR)

Christina Liu, PhD, PE, Program Director, Nanodelivery Systems and Devices Branch Pushpa Tandon, PhD, Program Director, Image Guided Intervention Branch Piotr Grodzinski, PhD, Chief, Nanodelivery Systems and Devices Branch Janet Eary, MD, Associate Director, Cancer Imaging Program

Expert Input and Consultation:

Giorgio Trinchieri, MD, Laboratory of Integrative Cancer Immunology, NCI/CCR Amiran Dzutsev, MD, PhD, Laboratory of Integrative Cancer Immunology, NCI/CCR Marina Dobrovolskaia, PhD, Immunology Section, NCI/NCL Howard Young, PhD, Cellular and Molecular Immunology Section, NCI/CCR Stephen Hewitt, MD, PhD, Laboratory of Pathology, NCI/CCR David Wink, PhD, Laboratory of Cancer Immunometabolism, NCI/CCR

Molecular Imaging Techniques to Characterize Cancer Inflammation

- Inflammation plays a role in cancer behavior and treatment outcomes
- The cellular physiology of cancer inflammation is not well understood;
- Cancer inflammation is dynamic and heterogeneous;
- In vivo imaging can quantitate cancer inflammation dynamics and heterogeneity non-invasively

Chronic Inflammation WG Established in Sept 2016, ICs: NCI, NIA, NIDCR, NIAID, NINR, NEI, NHLBI, NIDDK, ODS NCI Divisions: DCTD (CIP, CTEP), DCCPS, DCP, DCB

Trans-NIH Workshops on Chronic Inflammation



Workshop on Chronic Inflammation Biomarkers in Disease Development and Prevention

May 31-June 1, 2017

Rockville, Maryland

Mechanisms, biomarker discovery, imaging and sensing, big data analysis, clinical implications

Workshop on Imaging Inflammation and its Resolution in Health and Disease

> June 10-11, 2019 Rockville, Maryland

Aligning Imaging Capabilities to Address Challenges in Clinical Decisions and Patient Care

To date:

- A large amount of epidemiological data;
- Emerging *in vivo* imaging techniques, mostly for studies of inflammation in other diseases.

Needed:

- Longitudinal data;
- Multiple markers;
- Fast imaging tools;
- Imaging approaches for clinical decisions concerning cancer inflammation.

Research Grants and Awards on in vivo Imaging Inflammation Across NIH





Develop molecular imaging approaches for characterizing the dynamics of cancer associated inflammation

Bring inflammation molecular imaging to Cancer applications

Research Examples - In vivo Molecular Imaging Inflammation

Techniques to characterize immunometabolism

Techniques to follow inflammation-related molecules and molecular events over time

Anti-IL-22 Ab

MRI of cellular oxygenation & metabolites

NPL k_{PL} overlay HP ¹³C SA (s^{-1}) 0.016 0.004

Hyperpolarized 1-[13C]-Pyruvate Magnetic **Resonance Imaging Detects an Early Metabolic** Response to Androgen Ablation Therapy in Prostate Cancer. Aggarwal et al., Eur Urol. 2017 Dec;72(6):1028-1029

Apo-S-Ac₃ManNAz- and TRAIL-treated tumor tissues in PC-3 tumor-bearing mice model. Shim, et al, Sci Rep. 2017; 7: 16635. online 2017 Nov 30.





NIR of apoptotic tumor areas

SPECT/CT of fibroblast activator protein (FAP) tracer. 111In-28H1 can serve as a surrogate biomarker for reduced IL-22 levels. Van der Geest et al., Rheumatology Jan 18, 2018.

Many promising molecular imaging probes have been developed for pre-clinical in vivo imaging studies in non-cancer applications (concept Appendix).

Research Projects for Molecular Imaging Inflammation in Cancer (MIIC) Topics and Scope

Molecular imaging capabilities: Non-invasive, repeatable, fast, quantitative, specific, sensitive, high spatial resolution, robust image/data analysis

Dynamic measurements: inflammatory cellular physiology signatures, interactions and spatial information (examples below); studies of inflammatory pathways (i.e., NF-kB, STAT3, HIF)

Molecular (M)	Cellular (C)	Functional (F)	Structural (S)
CRP, IL-6, IL-10, MMP9, TLR9, IL-8, VCAM-1, ICAM- 1, TLR4, IFN-g, fatty acids and receptors, oncogenes, DNA mutations	Immune cells Macrophages Stem cells Microbiota	Tissue oxygenation Fat flux Metabolites	Lesion Tissue integrity Tissue stiffness

Bring inflammation molecular imaging to Cancer applications

Cancer types focus: Cancers with known inflammatory association (non-viral origin): pancreatic, prostate, colon, urinary bladder, breast

Research Projects on Molecular Imaging Inflammation in Cancer (MIIC)

Funding mechanism, receipt dates, and reviews

- R01 PAR: five-year R01s
- Two receipt dates per year coinciding with the standard receipt dates (Feb 5 & Oct 5) to ensure sufficient submissions for each receipt date;
- Reviewed by appropriate CSR standing study sections (i.e., CTIS, ITD, EITA, RTB, IPCA, IGIS);
- Including special review criteria.